Publication | Closed Access

Blocking MARCO+ tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway

Cancer ImmunosurveillanceHepatocellular CarcinomaImmunologyImmune Checkpoint InhibitorMarco+ Tumor-associated MacrophagesSting-ifn TypeLiver CancerImmunotherapyMedicineRadiation OncologyTumor Microenvironment